6/20/2019 8:38:10 AM
Celsion Announces IRB Approval To Begin Clinical Study Of ThermoDox Plus HIFU
12/18/2018 8:22:54 AM
DMC Completes Planned Safety And Data Review Of Celsion’s Phase III OPTIMA Study Of ThermoDox
12/3/2018 9:22:39 AM
Celsion Receives $11.1 Mln Allocation Through New Jersey Technology Business Tax Certificate Transfer Program
10/24/2018 9:27:09 AM
Celsion Announces PFS Data From GEN-1 Phase I Immuno-Oncology Study Of Patients With Stage III/IV Ovarian Cancer
10/22/2018 9:23:17 AM
Celsion Announces Publication Highlighting Potential Of Celsion's Gene-Mediated Immunotherapy
9/5/2018 8:12:37 AM
Celsion Announces Enrollment Completion For Pivotal Phase III OPTIMA Study Of ThermoDox In Primary Liver Cancer
7/10/2018 8:09:35 AM
Celsion Announces Publication Of Thermodox Phase I Study Results In The Lancet Oncology
6/28/2018 8:32:53 AM
Celsion Enters $10 Mln Loan Agreement With Horizon Technology Finance
5/11/2018 8:17:01 AM
Celsion Q1 Net Loss $4.5 Mln Or $0.25/Shr Vs Loss Of $5.2 Mln Or $3.09/Shr Last Year
3/27/2018 8:37:42 AM
Celsion Corp FY Loss Attributable To Shareholders $20.7 Mln Or $2.72/Sr Vs Loss $22.1 Mln Or $11.89/Shr Last Year
1/18/2018 8:08:17 AM
Celsion Provides Corporate Update; Reports Cash Position Of $25.5 Mln At Year-End 2017